Updated Jul 16, 2026
Celano Michael is a corporate insider tracked by InsiderAlpha. No SEC Form 4 filings recorded in the last 90 days.
Michael Celano is the Chief Financial Officer of Larimar Therapeutics, Inc. (LRMR), a clinical-stage biotechnology company focused on developing cell-penetrating peptide-based therapies, including the Friedreich's ataxia candidate CTI-1601. SEC filings as of 2026-01-27 show Celano as an insider with one filing and no reported stock purchases or sales.
| Role | Insider |
|---|---|
| Notability | 42/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-01-27 | LRMR | Larimar Therapeutics, Inc. | A — Grant or award | 37.6K | $0.00 |
Michael Celano is the Chief Financial Officer of Larimar Therapeutics, Inc. (LRMR), a clinical-stage biotechnology company focused on developing cell-penetrating peptide-based therapies, including the Friedreich's ataxia candidate CTI-1601. SEC filings as of 2026-01-27 show Celano as an insider with one filing and no reported stock purchases or sales.…
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Celano Michael profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.